Study of extra cholesterol-lowering medicine after a recent heart attack
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests an extra medication (inclisiran) added to your usual cholesterol-lowering treatment, compared to usual treatment alone, to see if it further lowers 'bad' cholesterol after a recent heart attack.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have had a recent heart attack or a related heart problem (called acute coronary syndrome) within the last 7 days.
- Your cholesterol levels must be above a certain threshold — either if you are already on cholesterol medication or if you haven't taken any yet.
- You must have adequate kidney function (a simple blood test will confirm).
- You must be willing to follow the study procedures and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a new cholesterol-lowering drug, inclisiran, early during a hospital stay after a heart attack can help lower bad cholesterol (LDL) more effectively than usual care. It may reduce the risk of future heart problems.
This study tests whether coordinating care between your regular doctor and heart specialists helps manage chronic coronary disease. It focuses on people with high cholesterol despite taking strong statin medication.
This study tests whether a newer cholesterol-lowering injection, given early after a heart attack, helps keep the plaque in your arteries stable and reduces future risk. It compares the new medicine added to your usual statin treatment.
This trial tests if giving inclisiran early after a heart attack can lower cholesterol more effectively. It is for people who have had a recent heart attack and still have high LDL cholesterol despite taking statins.
This study tests a cholesterol-lowering injection (inclisiran) given soon after a heart attack, urgent heart procedure, or stroke. The goal is to see if it helps lower bad cholesterol quickly and safely.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
Hear when a new Acute Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.